India’s Supreme Court dismissed Roche’s petition and allowed Natco Pharma to sell a generic version of Evrysdi, the STAT report said. The court’s decision cleared the path for much lower‑cost access in India for a drug used to treat spinal muscular atrophy (SMA). STAT reported the generic will be marketed at a fraction of Roche’s list price, underscoring ongoing tensions between patented orphan medicines and access in low‑and‑middle‑income markets. The ruling could prompt similar challenges to high‑price rare disease drugs in jurisdictions balancing intellectual property with public health imperatives.